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Introduction
Individuals with prehypertensive blood pressure (BP) have an in-
creased risk of developing cardiovascular disease relative to those 
with optimal levels.
1) The Seventh Report of the Joint National 
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Background and Objectives: Prehypertension according to JNC7 is common and is associated with increased vascular mortality. The 
importance of management in high-normal blood pressure (BP) is underemphasized. 
Subjects and Methods: We analyzed major adverse cardiac events (MACEs) in the Korea Acute Myocardial Infarction Registry in normal 
BP (group I) and high-normal BP (group II) patients.
Results: Among 14871 patients, 159 (61±12.3 years, 122 males) satisfied the study indication. Six-month and one-year clinical follow-up 
rate was 88.9% and 85.8%, respectively. Group I had 78 patients (60.9±12.4 years). Group II had 81 patients (61.6±12.5 years). Demo-
graphics of patients were not different between groups. Treatment strategy was not different. Initial Thrombolysis in Myocardial Infarc-
tion flow grade 0 was less frequent in group II (n=32, 47.1%) than in group I (n=16, 21.9%) (p=0.001). Successful intervention rate was not 
different between group II (93.8%) and group I (97.1%) (p=0.590). Six-month MACE occurred in 3 patients in group I (4.4%) and 10 in group 
II (15.6%) (p=0.031). Compared with normal BP, the odds ratio for patients with high-normal BP was 1.147 (p=0.045, 95% confidence inter-
val 1.011-1.402) for 6-month MACE. 
Conclusion: Even though high-normal BP patients had a better baseline clinical status, the prognosis was poorer than patients with nor-
mal BP. Therapeutic BP target goal for the patients with acute myocardial infarction should be <140/90 mm Hg, which is recommended in 
JNC7. (Korean Circ J 2012;42:304-310)
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Committee on Prevention, Detection, Evaluation, and Treatment of 
High BP (JNC 7) defined a new entity termed “prehypertension” to 
reflect the growing evidence that systolic BP (SBP) values between 
120 and 139 mm Hg and diastolic BP (DBP) values between 80 and 
89 mm Hg are associated with an increased cardiovascular risk.
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The European Guidelines,
3) however, divide this population into two 
groups: those with SBP between 120 and 129 mm Hg or DBP between 
80 and 84 mm Hg are classified as normal, whereas those with SBP 
between 130 and 139 mm Hg or DBP between 85 and 89 mm Hg 
are classified as high-normal. Although the association of cardio-
vascular risk with elevated BP is well-accepted,
4) only a few studies 
have addressed the risks of major adverse cardiac events (MACEs) 
for the population with acute myocardial infarction (AMI) in the 
high-normal range. The importance of management in “high-nor-
mal BP” according to definition of European Society of Hyperten-
sion (ESH) and the European Society of Cardiology (ESC) seems to 
be underemphasized. We presently investigated the impact of 
high-normal BP on adverse cardiac events in the patients with AMI 
from the Korea Acute Myocardial Infarction Registry (KAMIR).
Subjects and Methods
Methods
Korea Acute Myocardial Infarction Registry is a Korean, prospec-
tive, open, observational, multicenter, on-line registry of AMI with 
support from the Korean Society of Cardiology since November 
2005. The 50 participating hospitals are capable of primary percu-
taneous coronary intervention (PCI). Details of the KAMIR have 
been published.
5) AMI was diagnosed by characteristic clinical pre-
sentation, serial changes on electrocardiogram suggesting infarc-
tion, and increase in cardiac enzymes.
6) ST-segment elevation myo-
cardial infarction (STEMI) was defined by new ST elevation in ≥2 
contiguous leads, measuring >0.2 mV in leads V 1-3, or 0.1 mV in all 
other leads. 
Demographic and clinical characteristics including age, gender, 
cardiovascular risk factors (hypertension, diabetes mellitus, hyper-
lipidemia, smoking status, and family history of coronary heart dise-
ase) and co-morbidities were identified. Hypertension was defined 
as previously diagnosed by a physician and/or receiving medication 
to lower BP. Hyperlipidemia was defined as previously diagnosed 
by a physician and/or receiving lipid-lowering drugs. Family history 
of coronary heart disease was defined as coronary heart disease in 
first-degree male relative <55 years old or coronary heart disease in 
first-degree female relative <65 years old. Height, weight, and body 
mass index (BMI) were measured at admission. Initial vital signs 
were measured and Killip class was evaluated at admission. Elec-
trocardiogram was recorded and analyzed in all patients by attend-
ing physicians and/or cardiologists. Blood samplings for baseline 
laboratory tests except lipid measurement were collected at ad-
mission or before PCI. Overnight fasting blood was also sampled for 
lipid levels. The left ventricular ejection fraction was determined by 
two-dimensional echocardiography during the index hospitalization. 
In-hospital complications and their management were also recorded.
Initial treatment strategy for patients with STEMI could include 
PCI, thrombolysis, or conservative treatment at the discretion of the 
attending physician. Primary PCI was defined as emergency PCI 
performed within 12 hours after admission or PCI in patients with 
continuing symptoms or cardiogenic shock, even after 12 hours. 
For patients with non-STEMI, initial treatment strategy could in-
clude early invasive PCI or conservative treatment based on cur-
rent guidelines, at the discretion of the attending physician. Early 
invasive PCI was defined as emergency PCI that was performed 
within 48 hours in patients with non-STEMI with remaining symp-
toms. Glycoprotein IIb/IIIa receptor blockers, thrombectomy devic-
es, predilatation balloons, and stents during index PCI were used at 
the decision of the interventional cardiologists. Epicardial coronary 
blood flow in the infarct-related artery before and after stent im-
plantation was graded according to the classification used in the 
Thrombolysis in Myocardial Infarction (TIMI) trials. Successful PCI 
was defined as a residual stenosis <50% in diameter with final 
TIMI grade 3 flow. Furthermore, prescription of optimal evidence-
based medications was encouraged in all indicated patients who 
had no contraindications to guideline-recommended drugs during 
index hospitalization or after discharge.
Patient population and end point
From November 2005 to May 2009, 14871 patients with a final di-
agnosis of AMI were enrolled in KAMIR. Of these patients, to avoid 
effects of autonomic nerve system, patients without history of hy-
pertension, present angina, present dyspnea, present bradycardia, 
and tachycardia were analyzed in this study. BP was measured with 
a practical manual for usual emergency rooms. Usually, these were 
single-measured values. There was no limitation of hypotension 
and the lowest SBP among them was 120 mm Hg. Present angina 
and dyspnea were defined according to patients subjective symp-
toms upon arrival at the emergency department. Bradycardia was 
defined as <60 beats/min. Tachycardia was defined as >100 beats/min. 
Among the 14871 patients, 159 patients (61±12.3 years, 122 ma-
les) satisfied the study inclusion criteria. We analyzed MACEs in-
cluding death, recurrent myocardial infarction, revascularization 
including repeat PCI (target lesion or target vessel revasculariza-
tion, or non-target vessel revascularization), and coronary artery 
bypass grafting in patients with normal BP (group I, n=78) and high-
normal BP (group II, n=81) according to ESH 2007 definition.
3) Cardi-
ac death was defined as death from pump failure, arrhythmia, or me-
chanical complications including ventricular septal rupture and 
free wall rupture. Follow-up data were obtained by reviewing medi-
cal records and/or telephone interview with patients. All data were 
entered into an electronic web-based case-report form.306  High-Normal Blood Pressure in Myocardial Infarction
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Statistical analyses
Continuous variables were presented as the mean value±SD, com-
parisons were conducted by 2-tailed Student’s t-test. Discrete vari-
ables were presented as percentages and relative frequencies and 
comparisons were conducted by chi-square statistics or Fisher’s 
exact test as appropriate. Logistic regression analysis was perform-
ed to identify the independent predictors of MACEs with a 95% 
confidence interval (CI). The Kaplan-Meier method was used to es-
timate the risk of MACEs up to about 360 days, stratified by normal 
or high-normal BP. The Statistical Package for the Social Sciences 
(SPSS) for Windows, version 15.0 (SPSS Inc., Chicago, IL, USA) was 
used for all analyses. The level of significance for this study was 0.05.
Results
Among 14871 patients, 159 patients (61±12.3 years, 122 males) 
satisfied the study incision criteria. Group I had 78 patients (60.9± 
12.4 years). Group II had 81 patients (61.6±12.5 years). BP of group 
I was 120±1.6/77±6.3 mm Hg. BP of group II was 130±2.0/82±7.7 
mm Hg. BP of group II was higher (p<0.001). However, at discharge, 
there was no statistical difference of BP (group I=116±10.7/73± 
7.9 mm Hg, group II=113±20.1/75±9.2 mm Hg, p=0.389). Baseline 
clinical characteristics and initial presentation of patients are listed 
in Table 1. There were no significant differences in demographics, 
initial presentation, and vital signs.
Past medical histories were not different (Table 1). The preval-
ence of diabetes, dyslipidemia, smoking history, familial history, and 
BMI were not different between groups. STEMI was 43.6% of group 
I and 44.6% of group II.
Baseline laboratory characteristics are listed in Table 2. Left ven-
tricular ejection fraction, levels of peak creatine kinase-Mo full term 
myocardial bind, serum creatinine, high-sensitivity C-reactive pro-
tein, and N-terminal pro-B-type natriuretic peptide did not differ-
ent. The level of total cholesterol was not different, but the level of 
high density lipoprotein-cholesterol was higher in group II (43.1± 
12.7 mg/dL vs. 47.8±13.9 mg/dL, respectively; p=0.032).
Initial treatment strategy and discharge medications were not 
different (Table 3). 
The angiographic and procedural data are shown in Table 4. Left 
main coronary artery disease and three-vessel disease were not 
different between groups. There were no significant differences 
between groups in number of left anterior descending coronary 
artery. There were no significant differences between groups in le-
Table 1. Baseline clinical characteristics and past medical history
Group I
(n=78)
Group II
(n=81)
p
Age (years) 60.9±12.4 61.6±12.5 0.748
Women (%) 19 (24.1) 19 (23.5) 0.930
Height (cm) 164.8±8.9 163.5±9.0 0.382
Body weight (kg) 63.6±10.3 61.9±11.3 0.327
BMI (kg/m
2) 23.4±3.2 23.0±2.7 0.397
Initial presentation
    Prehospital resuscitation (%) 0 (0.0) 0 (0.0) NA
    Preinfarct angina pectoris (%) 0 (0.0) 0 (0.0) NA
    Dyspnea (%) 0 (0.0) 0 (0.0) NA
    Systolic blood pressure (mm Hg) 120.4±1.7 130.8±2.1 0.001
    Diastolic blood pressure (mm Hg) 77.2±6.3 82.1±7.7 0.001
    Heart rate (beats/min) 73.4±10.8 75.8±9.8 0.153
Previous coronary heart disease (%) 13 (16.5) 9 (11.1) 0.226
Previous angina (%) 3 (3.8) 2 (2.5) 0.780
Previous coronary artery bypass 
  grafting (%)
0 (0.0) 0 (0.0) NA
Previous PCI (%) 9 (5.4) 7 (7.9) 0.647
Hypertension (%) 0 (0.0) 0 (0.0) NA
Diabetes mellitus (%) 16 (20.5) 15 (28.5) 0.453
Hyperlipidemia (%) 6 (7.7) 6 (7.4) 0.570
Current smoker (%) 55 (69.6) 50 (61.7) 0.188
Family history of coronary heart 
  disease (%)
2 (2.6) 3 (3.7) 0.519
Previous cerebrovascular attack (%) 4 (5.1) 3 (3.7) 0.486
Data expressed as mean±SE or number of patients (percentage). BMI: body 
mass index, PCI: percutaneous coronary intervention, SE: standard error, 
NA: not available
Table 2. Baseline laboratory characteristics
Group I
(n=78)
Group II
(n=81)
p
Left ventricular ejection fraction 53.9±10.6 54.8±12.0 0.626
Peak creatine kinase-Mo full 
  term MB (ng/mL)
83.6±118.2 93.7±137.8 0.625
Peak cardiac troponin I (ng/mL) 34.1±42.3 39.6±62.7 0.547
Glucose (mg/dL) 149.3±75.6 152.2±61.1 0.797
Serum creatinine (mg/dL) 1.3±2.3 1.1±1.3 0.586
Total cholesterol (mg/dL) 178.0±49.3 188.5±48.6 0.184
Triglyceride (mg/dL) 115.7±66.1 127.8±74.7 0.294
High density lipoprotein- 
  cholesterol (mg/dL)
43.1±12.7 47.8±13.9 0.032
Low density lipoprotein- 
  cholesterol (mg/dL)
118.4±37.2 123.0±43.2 0.490
High-sensitivity C-reactive 
  protein (mg/dL)
1.9±2.8 2.9±9.9 0.446
N-terminal pro-B-type  
  natriuretic peptide (pg/mL)
994.3±1592.6 1040.7±1562.6 0.878
Data expressed as mean±SE or number of patients (percentage). SE: stan-
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sion types of American College of Cardiology/American Heart As-
sociation criteria. Initial TIMI flow grade was better in group II. Final 
TIMI flow grade was not different. The deployed stent profile, such 
as type, length, and diameter were not different between groups. 
Door to balloon time was not different. PCI success rate was not 
different.
In-hospital death occurred in 0 (0.0%) vs. one (1.3%) patient (p= 
0.319). One-month composite MACE occurred in zero (0.0%) vs. 
seven (10.3%) patients (p=0.006) (Table 5). The latter seven includ-
ed three (4.4%) cardiac deaths, two (2.9%) repeat PCIs, and two 
(2.9%) coronary artery bypass grafts. Six-month clinical follow-up 
rate were 88.9%. Thirteen (9.9%) developed MACE 6 months after 
the index treatment. Six-month composite MACE occurred in three 
(4.4%) vs. 10 (15.6%) patients (p=0.031) (Table 6). The former three 
(4.4%) were repeat PCIs. 
The later 10 included three (4.7%) cardiac deaths, five (7.8%) re-
peat PCIs, and two (3.1%) coronary artery bypass grafts. One-year 
clinical follow-up rate were 85.8%. Seventeen (13.6%) developed 
MACE 1 year after the index treatment. The former six included 
one (1.5%) cardiac death, four (6.0%) repeat PCIs, and one (1.5%) 
coronary artery bypass graft. The later 11 included 3 (5.2%) cardiac 
deaths, six (10.3%) repeat PCIs, and two (3.4%) coronary artery by-
pass grafts. Cumulative MACEs-free survival was better in group I 
than in group II (p=0.049) (Fig. 1).
Compared with group I, the odds ratio for group II was 1.181 (p= 
0.045, 95% CI, 1.011-1.402) for 6-month composite MACEs (Table 7). 
In multivariate logistic regression analysis, SBP was independent 
of age, gender, diabetes mellitus, familial history of coronary heart 
disease, N-terminal pro-B-type natriuretic peptide, and left main 
stem disease, as a predictor of MACEs at 6 months after AMI. How-
ever, group II did not have statistical significance to predict 12- 
Table 3. Treatment strategies in patients with normal and high-normal 
blood pressure
Group I 
(n=78)
Group II 
(n=81)
p
ST segment elevation MI (%) (n=32) (n=33) 0.546
    Primary PCI 21 (65.6) 18 (54.5)
    Facilitated PCI 1 (3.1) 4 (12.1)
    Thrombolytic therapy 6 (18.8) 6 (18.2)
    Conservative treatment 4 (12.5) 5 (15.2)
Non-ST-elevation MI (%) (n=38) (n=41) 0.424
    Early invasive therapy 28 (73.7) 32 (78.0)
    Early conservative therapy 10 (26.3) 9 (22.0)
Discharge medication (%)
    Aspirin 76 (98.7) 73 (97.3) 0.490
    Clopidogrel 71 (92.2) 68 (90.7) 0.480
    ß blockers 60 (77.9) 55 (73.3) 0.319
ACE 
  inhibitors or angiotensin II 
  receptor blockers
66 (85.7) 64 (85.3) 0.565
    Lipid-lowering drugs 51 (66.2) 54 (72.0) 0.277
    Nitrates 45 (58.4) 38 (50.7) 0.212
    Calcium channel blockers 3 (3.9) 7 (9.3) 0.153
MI: myocardial infarction, PCI: percutaneous coronary intervention, ACE: 
angiotensin-converting enzyme
Table 4. Angiographic and procedural data in each group
Group I 
(n=78)
Group II 
(n=81)
p
Coronary artery disease (%)
    Left main coronary artery, isolated 0 (0.0) 0 (0.0)
    Left main coronary artery, complex 4 (5.7) 2 (2.6) 0.352
    1-vessel disease 27 (38.6) 43 (56.6) 0.030
    2-vessel disease 21 (30.0) 20 (26.3) 0.624
    3-vessel disease 18 (25.7) 11 (14.5) 0.090
Infarct-related artery (%)
    Left main coronary artery stem 2 (2.9) 2 (2.6) 0.923
    Left anterior descending coronary artery 37 (53.6) 34 (44.7) 0.288
    Left circumflex coronary artery 10 (14.5) 22 (28.9) 0.036
    Right coronary artery 20 (29.0) 18 (23.7) 0.472
ACC/AHA lesion type (%)
    A 0 (0.0) 3 (4.1) 0.097
    B1 17 (25.8) 17 (23.3) 0.737
    B2 24 (36.4) 27 (37.0) 0.940
    C 25 (37.9) 26 (35.6) 0.784
Initial TIMI flow grade 0 (%) 32 (47.1) 16 (21.9) 0.001
Stent implantation (%) 60 (85.7) 62 (81.6) 0.504
Stent type (%)
    Bare metal stent 6 (10.0) 4 (6.5) 0.479
    Sirolimus-eluting stent 20 (33.3) 21 (33.9) 0.950
    Paclitaxel-eluting stent 27 (45.0) 28 (45.2) 0.986
    Zotarolimus-eluting stent 2 (3.3) 5 (8.1) 0.265
    Other drug-eluting stent 5 (8.3) 4 (6.5) 0.694
Stent length (mm) 26.3±5.8 26.6±7.3 0.812
Stent diameter (mm) 3.20±0.40 3.10±0.36 0.155
Use of platelet glycoprotein IIb/IIIa
  inhibitor (%)
8 (25.0) 8 (32.0) 0.568
Final TIMI flow grade 3 (%) 62 (93.9) 63 (92.6) 0.828
Door to balloon time (hour) 1.1±1.4 1.2±1.5 0.253
PCI success rate (%)* 60 (93.8) 66 (97.1) 0.590
Data expressed as mean±SE or number of patients (percentage). *Success-
ful PCI was defined as a residual stenosis <50% in diameter with final TIMI 
grade 3 flow. ACC/AHA: American College of Cardiology/American heart 
association, TIMI: Thrombolysis in Myocardial Infarction, PCI: percutaneous 
coronary intervention, SE: standard error308  High-Normal Blood Pressure in Myocardial Infarction
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month composite MACE.
Discussion
We analyzed MACEs after AMI in patients with normal BP and 
high-normal BP. Baseline status was very similar in both groups. 
Treatment strategy and medication was not different between gr-
oups. The patients with high-normal BP had more MACEs and poor 
survival 6 months after index treatment.
The United States is facing a serious challenge in the prevention 
and management of prehypertension and hypertension. People’s 
awareness and control of hypertension remain poor.
7) High-normal 
BP is common and is associated with increased vascular mortality. 
The results of a multiple ethnic groups investigation has demon-
strated that high-normal BP is a risk factor for incidence of coronary 
heart disease in both men and women.
8) In a Japanese cohort study, 
high-normal BP was revealed to be a risk factor for the incidence 
of stroke and MI in the general urban men population.
4) The extent 
to which it increases risk of cardiac death, recurrent MI, repeat PCI, 
and coronary artery bypass grafting after treatments of AMI is not 
clear. Some investigators reported that pre-hypertension appeared 
to be associated with an increased risk of MI and coronary artery 
disease but not stroke.
9) Some study reported that at 6-month fol-
low-up, age- and gender-adjusted odds ratios for adverse events 
were equivalent in hypertensives and normotensives after an initial 
acute coronary syndrome.
10) The authors explained this interesting 
result with the fact that treatment for the patients with hyperten-
sion was better tailored. In our study, there were no differences in 
treatment strategy and discharge medications.
The main finding of this study was that the patients with high-
normal BP, which was measured in the emergency room, have poor 
prognosis 6 months after index treatment. Interestingly, this study 
had a very well-conditioned baseline state comparable with pro-
spective studies. Among the dozens of baseline parameters, only 
high density lipoprotein-cholesterol level was not statistically equal. 
Thus, this study does not need to be adjusted to reduce confound-
Table 5. Clinical outcomes during follow-up: in-hospital death and one 
month MACE
Group I
(n=74)
Group II
(n=76)
p
In-hospital death (%) 0 (0.0) 1 (1.3) 0.319
One month MACE (5.0%) (%) (n=70) (n=68)
    Any MACE 0 (0.0) 7 (10.3) 0.006
    Cardiac death 0 (0.0) 3 (4.4) 0.076
    Non-cardiac death 0 (0.0) 0 (0.0) NA
    All cause death 0 (0.0) 3 (4.4) 0.076
    Recurrent MI 0 (0.0) 0 (0.0) NA
    Repeat PCI 0 (0.0) 2 (2.9) 0.148
    Coronary artery bypass grafting 0 (0.0) 2 (2.9) 0.148
MI: myocardial infarction, PCI: percutaneous coronary intervention, MACE: 
major adverse cardiac event, NA: not available
Table 6. Clinical outcomes during follow-up: six-month MACE
Six-month MACEs (9.8%)
Group I
(n=68)
Group II
(n=64)
p
Any MACE (%) 3 (4.4) 10 (15.6) 0.031
Cardiac death (%) 0 (0.0) 3 (4.7) 0.071
Noncardiac death (%) 0 (0.0) 0 (0.0) NA
All cause death (%) 0 (0.0) 3 (4.7) 0.071
Recurrent MI (%) 0 (0.0) 0 (0.0) NA
Repeat PCI (%) 3 (4.4) 5 (7.8) 0.413
Coronary artery bypass  
  grafting (%)
0 (0.0) 2 (3.1) 0.142
MI: myocardial infarction, PCI: percutaneous coronary intervention, MACE: 
major adverse cardiac events, NA: not available
Table 7. Multivariate logistic regression analysis for predicting six-month 
major adverse cardiac events
Variable OR (95% CI) p
Age 1.019 (0.954-1.088) 0.575
Female gender 3.898 (0.388-39.198) 0.248
Systolic blood pressure 1.181 (1.011-1.402) 0.045
Low density lipoprotein-cholesterol 0.975 (0.950-1.020) 0.056
Initial TIMI flow grade 1.419 (0.739-2.726) 0.293
N-terminal pro-B-type natriuretic 
  peptide
0.332 (0.096-1.145) 0.102
Left main stem disease 1.631 (0.184-31.859) 0.353
TIMI: Thrombolysis in Myocardial Infarction, CI: confidence interval, OR: 
odds tadio
Fig. 1. Cumulative major adverse cardiac events (MACE) free survival in 
group I (solid black line, normal blood pressure) and group II (dotted black 
line, high-normal blood pressure) using Kaplan-Meier analysis.
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ing variables. Even though group II had generally better known 
prognostic factors, such as higher high density lipoprotein-choles-
terol, more single vessel diseases, and higher TIMI flow grade, group 
II had poor 6-month MACEs and poor survival curve. It shows that 
high-normal BP affects on prognosis more than lipid profile and an-
giographic findings. In other words, it shows that more delicate BP 
control is needed to prevent MACEs after AMI.
Antecedent hypertension interacts with age, neurohumoral activ-
ation, and early ventricular remodeling to confer greater risk of he-
art failure after MI.
11) High-normal BP has also been associated with 
increased risk of carotid atherosclerosis.
12) We think our results can 
be explained with the conclusion that the patients with tightly 
controlled BP have less progression of atheroma than the patients 
without tightly controlled BP. Sipahi et al.
13) compared the effects 
of normal, pre-hypertensive, and hypertensive BP levels on progres-
sion of coronary astherosclerosis. In that report, those with hyper-
tensive BP levels displayed an increase in atheroma volume on an 
arterial segment, those with pre-hypertensive BP levels had an in-
termediate outcome, and those with normal BP levels had a trend 
for atheroma regression. Patients who improved from a pre-hyper-
tensive BP level at baseline to normal BP levels during the study had 
significantly less progression of atheroma than patients who re-
mained pre-hypertensive. That study suggested that in patients 
with coronary artery disease, the optimal BP goal may be substan-
tially lower than 140/90 mm Hg as BP levels may have a negative cor-
relation with atheroma progression.
13) We suggest that benefits can 
be obtained by controlling high-normal BP more tightly in patients 
with coronary artery diseases.
Medications including beta blockers, ACE inhibitors, and angio-
tensin converting enzyme inhibitors are needed for better progno-
sis after AMI. In some studies, administration of amlodipine to pati-
ents with coronary artery disease and normal BP resulted in reduc-
ed adverse cardiovascular events. Directionally similar, but smaller 
and not significant, treatment effects were observed with enala-
pril. For amlodipine, intravascular ultrasound showed evidence of 
slowing of atherosclerosis progression.
14) In our study, treatment 
strategy and medication was not different between groups.
In patients with hypertension and diabetes or renal disease, the 
BP goal is <130/80 mm Hg according to JNC7.
2) The target BP goal 
is <130/80 mm Hg in diabetics and in high or very high risk pati-
ents according to the ESC and ESH 2007 guidelines.
3) What should 
we do for high risk patients without definite hypertension, in case 
of prehypertension according to JNC7 and normal or high-normal 
hypertension according to ESC/ESH 2007, especially after AMI? 
Even though high-normal BP patients had better baseline clinical 
situation, follow-up MACE was poorer in the KAMIR patients than 
in patients with normal BP. This seems to confirm the importance 
of BP control in high-normal BP patients. The therapeutic BP target 
goal for the high-normal BP patients with AMI should be <140/90 
mm Hg, which is recommended in JNC7 and should be as low as 
130/80 mm Hg according to the ESC and ESH 2007 guidelines, even 
though the patients do not have definite hypertension.
Even though this study population was relatively small, the pa-
tients characteristics were very similar to the total KAMIR popula-
tion, which is revealed by similar MACEs rate to total population.
15) 
Total 6-month MACEs rate was 8.0% and our 6-month MACEs rate 
was 9.8%. When one-month MACEs were excluded, there was no 
difference of 6-month and 1-year MACEs. These findings are com-
patible with a previous report about KAMIR.
15) According to that 
report, initial in-hospital instabilities such as shock and angiogra-
phic severity were responsible for 6-month MACEs. In other words, 
one-month MACEs affect 6-month MACEs. Also, baseline charac-
teristics between the groups were similar enough to require no 
adjustment. Thus, those characteristics could overcome study limi-
tation such as small study population number. Finally, we believe 
that high normal BP, which was measured in the emergency room, 
could predict 6-month MACEs dependently of 1-month MACE. 
Our study has several other limitations. The study was based on 
a single measurement of BP, which may lead to a mis-classification 
of BP levels. It is more appropriate to compare BP management 
during follow-up to reduce bias related to BP measurement. Actu-
ally, we had compared BP at discharge. There was no difference 
between groups, perhaps as a result of a similar effort to control 
MI using angiotensin converting enzyme inhibitors or angiotensin 
receptor blockers, calcium channel blockers, and beta blockers, as 
several options. Even though there was no difference of BP after ma-
nagement, the prognosis was different. So, it may be valuable to 
evaluate initial BP in the emergency room. To avoid effects of au-
tonomic nerve system, we enrolled patients without present angi-
na, present dyspnea, present bradycardia, or tachycardia. Thus, we 
could have small number of population. So, those filters in patient 
selection might cause selection-bias in analysis. One-year clinical 
follow-up rate was 85.8% in this study. 
Conclusively, although high-normal BP patients had better base-
line clinical situation, follow-up MACEs were poorer in KAMIR than 
patients with normal BP. It shows that high-normal BP has adverse 
impacts on cardiac events in AMI. Therefore, strict BP controls are 
needed to prevent adverse cardiac events after AMI.
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